Group items tagged

This FOA encourages applications that develop, strengthen, and evaluate transdisciplinary approaches, methods, and investigative teams in basic behavioral, social, and/or biobehavioral research to generate fundamental knowledge of the reciprocal linkages between sleep and stress. Stress can result in sleep disruption due to both psychological as well as physiological changes. Sleep disruption can result in physiological changes; however, individuals may not recognize or identify impairment due to sleep disruption. This initiative supports the development of research teams to understand how basic individual, social, biological, and environmental factors interact in a dynamic relationship between sleep patterns and psychosocial stress to influence health, wellness, disease, and/or treatment adherence.

This FOA encourages applications that develop, strengthen, and evaluate transdisciplinary approaches, methods, and investigative teams in basic behavioral, social, and/or biobehavioral research to generate fundamental knowledge of the reciprocal linkages between sleep and stress. Stress can result in sleep disruption due to both psychological as well as physiological changes. Sleep disruption can result in physiological changes; however, individuals may not recognize or identify impairment due to sleep disruption. This initiative supports the development of research teams to understand how basic individual, social, biological, and environmental factors interact in a dynamic relationship between sleep patterns and psychosocial stress to influence health, wellness, disease, and/or treatment adherence.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.

The purpose of this Funding Opportunity Announcement is to invite applications that investigate the mechanisms mediating the interactions between sleep and diabetes-related metabolism using deep metabolic phenotyping approaches in healthy human populations and those with metabolic and/or sleep disorders.

The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fieldsneuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry.

The purpose of this FOAs are to encourage mechanistic research to investigate the impact of sleep disturbances on chronic pain. The mechanisms and processes underlying the contribution of sleep disturbances to chronic pain development and maintenance may be very broad. This FOA encourages interdisciplinary collaborations by experts from multiple fieldsneuroscientists, psychologists,endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry.

The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.

To allow investigators time to plan and develop applications, the TSCRP is providing its strategic plan for award mechanisms to be offered in 2013 should funding become available. Congressional funds for the FY13 TSCRP have not yet been appropriated, and this document is not to be construed as an obligation by the government; there is no guarantee of funding for these planned mechanisms. Areas of Focus: The FY13 TSCRP encourages research projects applications that specifically address the critical needs of theTSC community in the following areas of focus: Genetic, epigenetic, and non-genetic modifiers of TSC. Identification and development of preclinical models and therapeutic strategies (e.g., cytotoxic agents, combination therapies). Identifying biomarkers for early detection, prognosis, and prediction of treatment outcomes (such as serum markers, imaging, electrophysiology, prenatal testing, and pharmacogenetics). Impact of TSC manifestations in adults (e.g., care management, age-specific pathogenesis, epidemiology, renal, reproductive issues, and lymphangioleiomyomatosis [LAM])). Long-term benefits and effects of mTOR inhibitors or other agents. Novel strategies for diagnosis, treatment, and prevention of TSC manifestations including those geared toward early identification and intervention. Understanding the cellular and molecular mechanisms of TSC and LAM pathogenesis. Understanding the mechanism and improving the treatment of epilepsy in TSC. Understanding the mechanism and improving treatment of TSC-associated neurocognitive disorders (TAND) including cognitive impairment, and psychiatric, behavioral, and sleep disorders.

This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.

The Autism Science Foundation is inviting applications for its Pre- and Postdoctoral Training Awards from graduate students, medical students, and postdoctoral fellows interested in pursuing careers in basic and clinical research relevant to autism spectrum disorders. The proposed training must be scientifically linked to autism and may be broadened to include training in a closely related area of scientific research, including but not limited to human behavior across the lifespan (language, learning, behavior, communication, social function, motor skills & planning, epilepsy, sleep, repetitive disorders), neurobiology (anatomy, development, neuroimaging), pharmacology, neuropathology, genetics, epigenetics, genomics, epigenomics, immunology, molecular and cellular mechanisms, studies employing model organisms and systems, and studies of treatment and service delivery. Special consideration will be given to projects focused on gender issues in autism. This includes studies examining the female protective effect, neurobiological and neuroanatomical examination of the female autism brain, diagnostic differences and challenges in females, the female phenotype, and health and lifespan issues, including vocational services and employment. ASF also invites studies focused on unaffected siblings and recurrence risk in the offspring of unaffected siblings. ASF is also interested in supporting research on the neurobiology and molecular biology of autism using post-mortem brain tissue. The one-year awards include $25,000 for predoctoral and medical students and $35,000 for postdoctoral students.

To support projects that apply new or existing tools to monitor and/or manipulate the 4D nucleome in the context of human health and disease. Any human disease or biological process relevant to NIHs mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant timeframes may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles.

To support projects from NIH-defined New Investigators that apply new or existing tools to monitor and/or manipulate the 4D nucleome (4DN) in the context of human health and disease. Any human disease or biological process relevant to NIHs mission may be proposed including environmental exposures (e.g. addictive substances, toxins, psychosocial stress), or studies across development or lifespan. Other relevant time frames may include but are not limited to: circadian rhythms, fasting and feeding cycles, reproductive cycles, and sleep/wake cycles.

The purpose of this FOA is to fund research centers that will establish longitudinal cohorts in rare HLBS diseases to investigate unaddressed research questions using epidemiologic study designs and methods that are appropriate for conditions affecting fewer than 200,000 persons in the US. These observational cohort studies should be designed to provide an evidence base for future interventional studies, including clinical trials; for developing better diagnostics than those that are currently available; for answering early translational questions; or for broader implementation of guidelines for managing these diseases. This program will provide opportunities to advance rare disease research using genetics and deep phenotyping to characterize the disease and to identify disease sub-types; to use data science methods that integrate clinical and patient-reported outcomes (PROs) with laboratory, imaging, environmental and -omics data to understand the natural history of disease; to generate data that differentiate patients with the same morphological phenotype but different genetic mutations and severity of outcomes; to elucidate genotype-phenotype interactions and multisystem phenotyping to develop reliable and valid predictive tools to determine who will respond to which treatments and when to intervene; and to encourage innovative methods such as telemedicine to include participants with rare diseases located in remote locations.